Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.
To see our full nondiscrimination statement, click here.
Campus Construction Update
Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience.
Click here to learn more about our campus redesign.
Robert A. Stern, PhD, is a neurologist at Boston Medical Center (BMC) and a professor of neurology at Boston University Chobanian and Avedisian School of Medicine. He is also the co-founder and director of Clinical Research for the Boston University Chronic Traumatic Encephalopathy (CTE) Center. His research focuses on the long-term consequences of repetitive head impacts, including the neuropathological risk
... factors (e.g., genetic and head impact exposure), neuroimaging, biomarker development, and clinical diagnosis and descriptions of the neurodegenerative disease, CTE. He is currently lead PI of an NINDS-funded, 7-year, multicenter project examining these issues. From 2010-2019, he was the Clinical Core Director of the NIA-funded Boston University Alzheimer’s Disease Center (ADC). He continues to work with the ADC as a Senior Investigator. In these roles, he oversees a multidisciplinary group of scientists and clinicians, directs the center’s longitudinal research registry, and directs several NIH- and industry-funded diagnostic, prevention, and treatment trials. His other areas of research include diagnosis, risk factors, and treatment of cognitive decline and neuropsychiatric dysfunction in aging. He has also published extensively on the psychometric properties of many widely used tests in neuropsychology, as well as the use of various instruments and biomarkers in the differential diagnosis of Alzheimer’s disease (AD) and AD Related Dementias (ADRD). In addition, he has developed several commonly used tests and instruments, including the Neuropsychological Assessment Battery (NAB).